Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2026-04-22 @ 12:04 PM
Study NCT ID:
NCT02211833
Status:
COMPLETED
Last Update Posted:
2014-08-08
First Post:
2014-08-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C518477', 'term': 'BI 2536'}, {'id': 'D000068437', 'term': 'Pemetrexed'}], 'ancestors': [{'id': 'D006147', 'term': 'Guanine'}, {'id': 'D007042', 'term': 'Hypoxanthines'}, {'id': 'D011688', 'term': 'Purinones'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005971', 'term': 'Glutamates'}, {'id': 'D024342', 'term': 'Amino Acids, Acidic'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D000600', 'term': 'Amino Acids, Dicarboxylic'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 41}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2006-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-08', 'lastUpdateSubmitDate': '2014-08-07', 'studyFirstSubmitDate': '2014-08-07', 'studyFirstSubmitQcDate': '2014-08-07', 'lastUpdatePostDateStruct': {'date': '2014-08-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-08-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum tolerated dose (MTD) of BI 2536 in combination with pemetrexed', 'timeFrame': 'up to 3 weeks', 'description': 'by occurrence of dose limiting toxicities (DLT)'}, {'measure': 'Number of patients with adverse events during combination therapy', 'timeFrame': 'up to 20 weeks', 'description': 'according to common terminology criteria for adverse events (CTCAE) 3.0'}], 'secondaryOutcomes': [{'measure': 'Objective tumor response after combination therapy', 'timeFrame': 'up to 20 weeks', 'description': 'according to Response Evaluation Criteria in Solid Tumours (RECIST)'}, {'measure': 'Duration of objective tumor response after combination therapy', 'timeFrame': 'up to 1 year'}, {'measure': 'Progression free survival (PFS)', 'timeFrame': 'up to 2 years'}, {'measure': 'Overall survival', 'timeFrame': 'up to 2 years'}, {'measure': 'Number of patients with abnormal laboratory findings', 'timeFrame': 'up to 20 weeks'}, {'measure': 'Change in Eastern Cooperative Oncology Group (ECOG) performance score', 'timeFrame': 'baseline, up to 1 year'}]}, 'conditionsModule': {'conditions': ['Carcinoma, Non-Small-Cell Lung']}, 'descriptionModule': {'briefSummary': 'Exploratory evaluation of safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD), and efficacy of BI 2536 administered in combination with pemetrexed'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Pathologic or cytologic confirmed diagnosis of NSCLC\n2. Recurrent, advanced or metastatic NSCLC that had progressed following 1 prior chemotherapy regimen for advanced disease. Patients could have received prior adjuvant chemotherapy as long as the disease free interval was longer than 1 year.\n3. Measurable disease by 1 or more techniques (CT, MRI) according to RECIST criteria\n4. Male or female aged 18 years or older\n5. Life expectancy of at least 3 months\n6. Eastern Cooperative Oncology Group (ECOG) performance score 0-2\n7. Written informed consent that was consistent with International Conference on Harmonization (ICH) - Good Clinical Practice (GCP) guidelines\n\nExclusion Criteria:\n\n1. Treatment with an investigational drug in another clinical study within the 28 days prior to the start of therapy or concomitantly with this study\n2. Anti-cancer therapy for NSCLC (except radiotherapy for palliative reasons) within the 28 days prior to Day 1 of treatment period 1 of this trial\n3. Any persisting toxicities that were deemed to be clinically significant from the previous therapy\n4. Received more than 1 prior chemotherapy regimen for advanced disease (not including prior adjuvant therapy). Patients could have received prior epidermal growth factor receptor tyrosine kinase inhibitors\n5. Unwilling or unable to take folic acid and vitamin B12 supplementation\n6. Active brain metastases (stable for \\<28 days, symptomatic, or requiring concurrent steroids). Patients who had received prior whole brain irradiation and whose brain metastases were stable according to the criteria above were not excluded\n7. Other active malignancy diagnosed within the past 3 years (other than non-melanomatous skin cancer and cervical intraepithelial neoplasia)\n8. Concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would have limited compliance with trial requirement or which were considered relevant for the evaluation of the efficacy or safety of the trial drug\n9. Unable or unwilling to interrupt concomitant administration of NSAIDS 5 days prior to the day of and up to 2 days after the administration of pemetrexed\n10. Received prior therapy with pemetrexed\n11. Absolute neutrophil count (ANC) ≤1 500/μL, platelet count ≤100 000/μL, or haemoglobin \\<9 mg/dL\n12. Total bilirubin \\>1.5 mg/dL (26 μmol/L), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2.5 x the upper limit of normal (ULN), except in cases of known liver metastasis where a maximum 5 x ULN was acceptable\n13. Serum creatinine level \\>1.5 mg/dL and or creatinine clearance \\<45 mL/min\n14. Sexually active and unwilling to use a medically acceptable method of contraception\n15. Pregnancy or breast feeding\n16. Known or suspected active alcohol or drug abuse\n17. Unable to comply with the protocol\n18. Any known hypersensitivity to the trial drugs or their excipients'}, 'identificationModule': {'nctId': 'NCT02211833', 'briefTitle': 'Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'A Phase I Open-label Dose Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer', 'orgStudyIdInfo': {'id': '1216.5'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'BI 2536 with pemetrexed', 'description': 'combination therapy phase may be followed by BI 2536 monotherapy for eligible patients', 'interventionNames': ['Drug: BI 2536', 'Drug: Pemetrexed']}], 'interventions': [{'name': 'BI 2536', 'type': 'DRUG', 'armGroupLabels': ['BI 2536 with pemetrexed']}, {'name': 'Pemetrexed', 'type': 'DRUG', 'armGroupLabels': ['BI 2536 with pemetrexed']}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}